, Volume 52, Issue 8, pp 703–709 | Cite as

Lipid transfers to HDL are diminished in long-term bedridden patients: association with low HDL-cholesterol and increased inflammatory markers

  • Wilson Pascoalino Camargo de Oliveira
  • Thauany Martins Tavoni
  • Fatima Rodrigues Freitas
  • Bruna Miranda Oliveira Silva
  • Raul Cavalcante Maranhão
Original Article


Plasma lipids have been extensively studied in sedentary and in subjects practicing exercise training, but not in extreme inactivity as occurs in bedridden patients. This is important for the care of bedridden patients and understanding the overall plasma lipid regulation. Here, we investigated plasma lipids, lipid transfers to HDL and inflammatory markers in bedridden patients. Fasting blood samples were collected from 23 clinically stable bedridden patients under long-term care (>90 days) and 26 normolipidemic sedentary subjects, paired for age and gender. In vitro transfer of four lipids to HDL was performed by incubating plasma with donor nanoparticles containing radioactive lipids. Total (193 ± 36 vs 160 ± 43, p = 0.005), LDL (124 ± 3 vs 96 ± 33 p = 0.003) and HDL-cholesterol (45 ± 10 vs 36 ± 13, p = 0.008), apolipoprotein A-I (134 ± 20 vs 111 ± 24, p = 0.001) and oxidized LDL (53 ± 13 vs 43 ± 12, p = 0.011) were lower in bedridden patients, whereas triglycerides, apolipoprotein B, CETP and LCAT were equal in both groups. Transfers of all lipids, namely unesterified cholesterol, cholesterol esters, triglycerides and phospholipids, to HDL were lower in bedridden patients, probably due to their lower HDL-cholesterol levels. Concentrations of IL-1β, IL-6, IL-8, HGF and NGF were higher in bedridden patients compared to sedentary subjects. In conclusion, inactivity had great impact on HDL, by lowering HDL-cholesterol, apolipoprotein A-I and thereby cholesterol transfers to the lipoprotein, which suggests that inactivity may deteriorate HDL protection beyond the ordinary sedentary condition.


High-density lipoproteins (HDL) Lipid metabolism Cholesterol ester transfer protein (CETP) Exercise training Nanoparticles 





Body mass index


Cholesterol ester transfer protein


High density lipoprotein


Hepatocyte growth factor




Low density lipoprotein


Lecithin-cholesterol acyltransferase


Monocyte chemotactic protein


Nerve growth factor


Reverse cholesterol transport


Tumor necrosis factor-α



The authors are thankful to Mrs. Josefa M.H.S. Lima BSc, for her help with the experiments.

Authors contribution

WPCO: patient selection, data collection, analysis and interpretation of data, manuscript writing. TMT: performance of experiments, analysis of data, manuscript writing. FRF: analysis of data, interpretation of results, manuscript writing. BMOS: performance of experiments. RCM: design and conduction of the study, manuscript writing, intellectual content. All authors read and approved the final manuscript.

Compliance with ethical standards


This study was supported by the São Paulo State Research Support Foundation (FAPESP, São Paulo, Brazil; Grant 14/03742-0). Dr. Maranhão has a Research Carrier Award from the National Council for Scientific and Technological Development (CNPq, Brasilia, Brazil).

Conflict of interest

The authors declare have no conflicts of interest.


  1. 1.
    Halverstadt A, Phares DA, Wilund KR, Goldberg AP, Hagberg JM (2007) Endurance exercise training raises high-density lipoprotein cholesterol and lowers small low-density lipoprotein and very low-density lipoprotein independent of body fat phenotypes in older men and women. Metabolism 56:444–450CrossRefPubMedGoogle Scholar
  2. 2.
    Durstine JL, Grandjean PW, Cox CA, Thompson PD (2002) Lipids, lipoproteins, and exercise. J Cardiopulm Rehabil 22:385–398CrossRefPubMedGoogle Scholar
  3. 3.
    Lira FS, Rosa JC, Lima-Silva AE, Souza HA, Caperuto EC, Seelaender MC, Damaso AR, Oyama LM, Santos RV (2010) Sedentary subjects have higher PAI-1 and lipoproteins levels than highly trained athletes. Diabetol Metab Syndr 22:2–7Google Scholar
  4. 4.
    Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT (2012) Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 380:219–229CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Wang M, Briggs MR (2004) HDL: the metabolism, function and therapeutic importance. Chem Rev 104:119–137CrossRefPubMedGoogle Scholar
  6. 6.
    Falk E (2006) Pathogenesis of atherosclerosis. J Am Coll Cardiol 47:C7–C12CrossRefPubMedGoogle Scholar
  7. 7.
    Yu R, Yekta B, Vakili L, Gharavi N, Navab M, Marelli D, Ardehali A (2008) Proatherogenic high-density lipoprotein, vascular inflammation, and mimetic peptides. Curr Atheroscler Rep 10:171–176CrossRefPubMedGoogle Scholar
  8. 8.
    Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM (2006) Mechanisms of disease: proatherogenic HDL—an evolving field. Nat Clin Pract Endocrinol Metab 2:504–511CrossRefPubMedGoogle Scholar
  9. 9.
    Tölle M, Huang T, Schuchardt M, Jankowski V, Prüfer N, Jankowski J, Tietge UJ, Zidek W, van der Giet M (2012) High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res 94:154–162CrossRefPubMedGoogle Scholar
  10. 10.
    Dullaart RP, de Boer JF, Annema W, Tietge UJ (2013) The inverse relation of HDL anti-oxidative functionality with serum amyloid A is lost in metabolic syndrome subjects. Obesity (Silver Spring) 21:361–366CrossRefGoogle Scholar
  11. 11.
    Lo Prete AC, Dina CH, Azevedo CH, Puk CG, Lopes NH, Hueb WA, Maranhão RC (2009) In vitro simultaneous transfer of lipids to HDL in coronary artery disease and in statin treatment. Lipids 44:917–924CrossRefPubMedGoogle Scholar
  12. 12.
    Maranhão RC, Freitas FR (2014) HDL metabolism and atheroprotection: predictive value of lipid transfers. Adv Clin Chem 65:1–41CrossRefPubMedGoogle Scholar
  13. 13.
    Barter JP (2000) CETP and atherosclerosis. Arterioscler Thromb Vasc Biol 20:2029–2031CrossRefPubMedGoogle Scholar
  14. 14.
    Huuskonen J, Olkkonen VM, Jauhiainen M, Ehnholm C (2001) The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis 155:269–281CrossRefPubMedGoogle Scholar
  15. 15.
    Albers JJ, Vuletic S, Cheung MC (2012) Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism. Biochim Biophys Acta 1821:345–357CrossRefPubMedGoogle Scholar
  16. 16.
    Vaisberg M, Bachi AL, Latrilha C, Dioguardi GS, Bydlowski SP, Maranhão RC (2012) Lipid transfer to HDL is higher in marathon runners than in sedentary subjects, but is acutely inhibited during the run. Lipids 47:679–686CrossRefPubMedGoogle Scholar
  17. 17.
    da Silva JL, Vinagre CG, Morikawa AT, Alves MJ, Mesquita CH, Maranhão RC (2011) Resistance training changes LDL metabolism in normolipidemic subjects: a study with a nanoparticle mimetic of LDL. Atherosclerosis 219:532–537CrossRefPubMedGoogle Scholar
  18. 18.
    Casella-Filho A, Chagas AC, Maranhão RC, Trombetta IC, Cesena FH, Silva VM, Tanus-Santos JE, Negrão CE, da Luz PL (2011) Effect of exercise training on plasma levels and functional properties of high-density lipoprotein cholesterol in the metabolic syndrome. Am J Cardiol 107:1168–1172CrossRefPubMedGoogle Scholar
  19. 19.
    Ginsburg GS, Ginsburg GS, Atikinson D (1982) Microemulsions of phospholipids and cholesterol esters. Protein-free models of low density lipoprotein. J Biol Chem 257:8216–8227PubMedGoogle Scholar
  20. 20.
    Maranhão RC, Cesar TB, Pedroso-Mariani SR, Hirata MH, Mesquita CH (1993) Metabolic behavior in rats of a non protein microemulsion resembling low-density lipoprotein. Lipids 28:691–696CrossRefPubMedGoogle Scholar
  21. 21.
    Barter P, Kastelein J, Nunn A, Hobbs R (2003) High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 168:195–211CrossRefPubMedGoogle Scholar
  22. 22.
    Vinagre CG, Ficker ES, Finazzo C, Alves MJ, de Angelis K, Irigoyen MC, Negrão CE, Maranhão RC (2007) Enhanced removal from the plasma of LDL-like nanoparticle cholesteryl ester in trained men compared with sedentary healthy men. J Appl Physiol 103:1166–1171CrossRefPubMedGoogle Scholar
  23. 23.
    Levitan I, Volkov S, Subbaiah PV (2010) Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal 13:39–75CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Parthasarathy S, Raghavamenon A, Garelnabi MO, Santanam N (2010) Oxidized low-density lipoprotein. Methods Mol Biol 610:403–417CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Jung RT (1997) Obesity as a disease. Br Med Bull 53:307–321CrossRefPubMedGoogle Scholar
  26. 26.
    Maranhão RC, Freitas FR, Strunz CM, Santos RD, Mansur AJ, Mansur AP (2012) Lipid transfers to HDL are predictors of precocious clinical coronary heart disease. Clin Chim Acta 413:502–505CrossRefPubMedGoogle Scholar
  27. 27.
    Sprandel MC, Hueb WA, Segre A, Ramires JA, Kalil-Filho R, Maranhão RC (2015) Alterations in lipid transfers to HDL associated with the presence of coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 14:107–115CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Rousset X, Shamburek R, Vaisman B, Amar M, Remaley AT (2011) Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor? Curr Atheroscler Rep 13:249–256CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Davies AL, Hayes KC, Dekaban GA (2007) Clinical correlates of elevated serum concentrations of cytokines and autoantibodies in patients with spinal cord injury. Arch Phys Med Rehabil 88:1384–1393CrossRefPubMedGoogle Scholar
  30. 30.
    Yang L, Blumbergs PC, Jones NR, Manavis J, Sarvestani GT, Ghabriel MN (2004) Early expression and cellular localization of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in human traumatic spinal cord injury. Spine 29:966–971CrossRefPubMedGoogle Scholar
  31. 31.
    Bank M, Stein A, Sison C (2015) Elevated circulating levels of the pro-inflammatory cytokine macrophage migration inhibitory factor in individuals with acute spinal cord injury. Arch Phys Med Rehabil 96:633–644CrossRefPubMedGoogle Scholar
  32. 32.
    Kwon BK, Stammers AM, Belanger LM, Bernardo A, Chan D, Bishop CM, Slobogean GP, Zhang H, Umedaly H, Giffin M, Street J, Boyd MC, Paquette SJ, Fisher CG, Dvorak MF (2010) Cerebrospinal fluid inflammatory cytokines and biomarkers of injury severity in acute human spinal cord injury. J Neurotrauma 27:669–682CrossRefPubMedGoogle Scholar
  33. 33.
    Bachi ALL, Rocha GA, Sprandel MCO, Ramos LR, Gravina CF, Pithon-Curi TC, Vaisberg M, Maranhão RC (2015) Exercise training improves plasma lipid and inflammatory profiles and increases cholesterol transfer to high-density lipoprotein in elderly women. J Am Geriatr Soc 63:1247–1249CrossRefPubMedGoogle Scholar
  34. 34.
    Porat O (1989) The effect of tumor necrosis factor alpha on the activity of lipoprotein lipase in adipose tissue. Lymphokine Res 8:459–469PubMedGoogle Scholar
  35. 35.
    Mackay AG, Oliver JD, Rogers MP (1990) Regulation of lipoprotein lipase activity and mRNA content in rat epididymal adipose tissue in vitro by recombinant tumour necrosis factor. Biochem J 269:123–126CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Marsche G, Saemann MD, Heinemann A, Holzer M (2013) Inflammation alters HDL composition and function: implications for HDL-raising therapies. Pharmacol Ther 137:341–351CrossRefPubMedGoogle Scholar
  37. 37.
    Burger D, Dayer JM (2002) High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation? Autoimmun Rev 1:111–117CrossRefPubMedGoogle Scholar

Copyright information

© AOCS 2017

Authors and Affiliations

  • Wilson Pascoalino Camargo de Oliveira
    • 1
    • 2
    • 3
  • Thauany Martins Tavoni
    • 1
    • 2
  • Fatima Rodrigues Freitas
    • 1
  • Bruna Miranda Oliveira Silva
    • 1
  • Raul Cavalcante Maranhão
    • 1
    • 2
    • 4
  1. 1.Lipid Metabolism Laboratory, Heart Institute (InCor), Medical School HospitalUniversity of São PauloSão PauloBrazil
  2. 2.Faculty of Pharmaceutical SciencesUniversity of São PauloSão PauloBrazil
  3. 3.Suzano Auxiliary Hospital, Medical School Hospital, University of São PauloSuzanoBrazil
  4. 4.Instituto do Coração (InCor) do Hospital das Clínicas, FMUSPSão PauloBrazil

Personalised recommendations